John M. Maris

Active 1985–2025

244
Papers
46,990
Citations
116
h-index
234
i10-index

Citations

Citations per year for John M. Maris1976: 1 citations1979: 1 citations1986: 4 citations1987: 5 citations1988: 8 citations1989: 3 citations1990: 4 citations1991: 6 citations1992: 6 citations1993: 12 citations1994: 7 citations1995: 6 citations1996: 14 citations1997: 18 citations1998: 10 citations1999: 27 citations2000: 50 citations2001: 68 citations2002: 79 citations2003: 95 citations2004: 78 citations2005: 110 citations2006: 117 citations2007: 177 citations2008: 231 citations2009: 244 citations2010: 371 citations2011: 340 citations2012: 410 citations2013: 323 citations2014: 426 citations2015: 399 citations2016: 411 citations2017: 548 citations2018: 582 citations2019: 1,659 citations2020: 1,782 citations2021: 1,879 citations2022: 1,471 citations2023: 1,128 citations2024: 1,646 citations2025: 888 citations2026: 27 citations1977–1978: no citations, so these years are not shown1980–1985: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,746 citing papers, 30.4% of this breakdownChina: 1,592 citing papers, 10.2% of this breakdownUnited Kingdom: 1,010 citing papers, 6.5% of this breakdownGermany: 975 citing papers, 6.2% of this breakdownItaly: 732 citing papers, 4.7% of this breakdownFrance: 609 citing papers, 3.9% of this breakdownCanada: 552 citing papers, 3.5% of this breakdownAustralia: 473 citing papers, 3% of this breakdownNetherlands: 468 citing papers, 3% of this breakdownSpain: 409 citing papers, 2.6% of this breakdownJapan: 399 citing papers, 2.6% of this breakdownSweden: 318 citing papers, 2% of this breakdown
0%30.4%Other 21.4%

Fields

  • Medicine60.9%
  • Biochemistry, Genetics and Molecular Biology31.7%
  • Immunology and Microbiology2.9%
  • Neuroscience1.8%
  • Computer Science0.7%
  • Engineering0.5%
  • Other1.5%

Topics

  • Neuroblastoma Research and Treatments8%
  • CAR-T cell therapy research4.9%
  • Cancer, Hypoxia, and Metabolism4%
  • Cancer Genomics and Diagnostics2.5%
  • Glioma Diagnosis and Treatment1.9%
  • Virus-based gene therapy research1.9%
  • Other76.8%

Coauthors

All papers

Open in search
  1. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2019 cited by 672

  2. Neuroblastoma

    Authors: , , , , , , - Nature Reviews Disease Primers 2016 cited by 1,428

  3. Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2015 cited by 1,254

  4. Recent Advances in Neuroblastoma

    Authors: - New England Journal of Medicine 2010 cited by 1,998

  5. Atomically accurate de novo design of antibodies with RFdiffusion

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Chang C. Liu, David Baker - Nature 2024 cited by 187

  6. Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

    Authors: , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2010 cited by 1,809

  7. Pan-cancer genome and transcriptome analyses of 1, 699 paediatric leukaemias and solid tumours

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Stephen P. Hunger, Daniela S. Gerhard, Jinghui Zhang - Nature, Nat. 2018 cited by 961

  8. Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group

    Authors: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 cited by 474

  9. Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Daniel Martínez, Deborah Lyon - Nature 2024 cited by 207

  10. Neuroblastoma

    Authors: , , , - The Lancet 2007 cited by 2,023

  11. Comprehensive Analysis of Hypermutation in Human Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Enrico Opocher, Gary Mason, Gregory A. Thomas, Magnus Sabel, Ben George, David S. Ziegler, Scott Lindhorst, Vanan Magimairajan Issai, Shlomi Constantini, Helen Toledano, Ronit Elhasid, Roula Farah, Rina Dvir, Peter B. Dirks, Annie Huang, Melissa A. Galati, Jiil Chung, Vijay Ramaswamy, Meredith S. Irwin, Melyssa Aronson, Carol Durno, Michael D. Taylor, Gideon Rechavi, John M. Maris, Éric Bouffet, Cynthia Hawkins, J Costello, M. Stephen Meyn, Zachary F. Pursell, David Malkin, Uri Tabori, Adam Shlien - Cell 2017 cited by 812

  12. GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Johanna Theruvath, José G. Vilches-Moure, Ansuman T. Satpathy, Howard Y. Chang, Manfred Lehner, Sabine Taschner‐Mandl, Jean-Phillipe Julien, Poul H. Sorensen, Dimiter S. Dimitrov, John M. Maris, Crystal L. Mackall - Cancer Cell 2021 cited by 163

  13. The genetic landscape of high-risk neuroblastoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Richard A. Moore, Karen Mungall, Jenny Q. Qian, Angela Tam, Nina Thiessen, Yongjun Zhao, Kristina A. Cole, Maura Diamond, Sharon J. Diskin, Yaël P. Mossé, Andrew Wood, Lingyun Ji, Richard Sposto, Thomas Badgett, Wendy B. London, Yvonne Moyer, Julie M. Gastier‐Foster, Malcolm A. Smith, Jaime M. Guidry Auvil, Daniela S. Gerhard, Michael D. Hogarty, Steven J.M. Jones, Eric S. Lander, Stacey Gabriel, Gad Getz, Robert C. Seeger, Javed Khan, Marco A. Marra, Matthew Meyerson, John M. Maris - Nature Genetics 2013 cited by 1,219

  14. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032

    Authors: , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2021 cited by 216

  15. Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children’s Oncology Group

    Authors: , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 cited by 191

  16. Identification of ALK as a major familial neuroblastoma predisposition gene

    Authors: , , , , , , , , , , , , , , , , , , , , , - Nature 2008 cited by 1,416

  17. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Anne Hakkert, Esther van Wezel, C. Ellen van der Schoot, Ellen M. Westerhout, Johannes H. Schulte, Godelieve A.M. Tytgat, M. Emmy M. Dolman, Isabelle Janoueix‐Lerosey, Daniela S. Gerhard, Huib N. Caron, Olivier Delattre, Javed Khan, Rogier Versteeg, Gudrun Schleiermacher, Jan J. Molenaar, John M. Maris - Nature Genetics 2015 cited by 555

  18. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma

    Authors: , , , , , , , , , , , , , , , , - JAMA 2019 cited by 357

  19. Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lei Qin, Ning Huang, Ana Guerreiro Stücklin, A. Sorana Morrissy, Florence M.G. Cavalli, Betty Luu, Raúl A. Suárez, Pasqualino De Antonellis, Antony Michealraj, Avesta Rastan, Meenakshi Hegde, Martin Komosa, Olga Sirbu, Sachin Kumar, Zied Abdullaev, Cláudia C. Faria, Stephen Yip, Juliette Hukin, Uri Tabori, Cynthia Hawkins, Ken Aldape, Mads Daugaard, John M. Maris, Poul H. Sorensen, Nabil Ahmed, Michael D. Taylor - Nature Medicine 2020 cited by 241

  20. Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Katherine K. Matthay, Esther R. Berko, John M. Maris, Araz Marachelian, Yaël P. Mossé - Nature Medicine 2023 cited by 125

  21. Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting

    Authors: , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 cited by 353

  22. Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Annika Bronsema, Vanan Magimairajan, Enrico Opocher, Rebecca Loret De Mola, Magnus Sabel, Charlotta A. Frojd, David Sumerauer, David Samuel, Kristina A. Cole, Stefano Chiaravalli, Maura Massimino, Patrick Tomboc, David S. Ziegler, Ben George, An Van Damme, Nobuko Hijiya, David Gass, Rose B. McGee, Oz Mordechai, Daniel C. Bowers, Theodore W. Laetsch, Alexander Lossos, Deborah T. Blumenthal, Tomasz Sarosiek, Lee Yi Yen, Jeffrey Knipstein, Anne Bendel, Lindsey M. Hoffman, Sandra Luna‐Fineman, Stefanie Zimmermann, Isabelle Scheers, Kim E. Nichols, Michal Zápotocký, Jordan R. Hansford, John M. Maris, Peter B. Dirks, Michael D. Taylor, Abhaya V. Kulkarni, Manohar Shroff, Derek S. Tsang, Anita Villani, Wei Xu, Melyssa Aronson, Carol Durno, Adam Shlien, David Malkin, Gad Getz, Yosef E. Maruvka, Pamela S. Ohashi, Cynthia Hawkins, Trevor J. Pugh, Éric Bouffet, Uri Tabori - Nature Medicine 2022 cited by 144

  23. Targeting of intracellular oncoproteins with peptide-centric CARs

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2023 cited by 75

  24. Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Cell 2017 cited by 228